Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD)

Fig. 1

NSCLC with COPD patients obtained a higher MPR rate to neoadjuvant immunotherapy. (A) The efficacy to neoadjuvant immunotherapy in NSCLC patients with different COPD status, age, smoking history, gender, clinical stage, PD-L1 expression, treatment cycles, and pathology were compared. (B) Representative pictures of HE staining of patients received neoadjuvant immunotherapy. Left: NSCLC with COPD; Right: NSCLC without COPD. (C) Statistical chart of HE staining in NSCLC with COPD versus NSCLC without COPD patients received neoadjuvant immunotherapy. Scale bars, 100 μm.*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us